Soleno Therapeutics, Inc. (SLNO) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Redwood City, CA, United States. The current CEO is Anish Bhatnagar.
SLNO has IPO date of 2014-11-13, 115 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $2.72B.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
